Mar 27, 2019   SOURCE: PR NewsWire

Diabetic Nephropathy Pipeline Insight Report 2019: Pipeline (Under Development), Therapeutics Scenario and Growth Prospects

DUBLIN, March 27, 2019 /PRNewswire/ -- The "Diabetic Nephropathy - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Diabetic Nephropathy development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Diabetic Nephropathy pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report 

    --  The report provides a snapshot of the pipeline development for the
        Diabetic Nephropathy
    --  The report covers pipeline activity across the complete product
        development cycle i.e. clinical, pre-clinical and discovery stages for
        the Diabetic Nephropathy
    --  The report provides pipeline product profiles which includes product
        description, developmental activities, licensors & collaborators and
        chemical information
    --  Provides pipeline assessment by monotherapy and combination therapy
        products, stage of development, route of administration, and molecule
        type for Diabetic Nephropathy
    --  The report also covers the dormant and discontinued pipeline projects
        related to the Diabetic Nephropathy

Reasons to Buy

    --  Establish comprehensive understanding of the pipeline activity across
        this Diabetic Nephropathy to formulate effective R&D strategies
    --  Gather information of the emerging competitors having potentially
        lucrative portfolio in this space and create effective counter
        strategies to gain competitive advantage
    --  Identify the relationship between the drugs and use it for target
        finding, drug repurposing, and precision medicine
    --  Plot corrective measures for pipeline projects by understanding the
        pipeline depth and focus of Diabetic Nephropathy therapeutics
    --  Devise in licensing and out licensing strategies by identifying
        prospective partners with the most attractive projects to enhance and
        expand business potential and scope
    --  Modify the therapeutic portfolio by identifying inactive projects and
        understanding the factors that might have halted their progress

Key Topics Covered:

1. Report Introduction

2. Diabetic Nephropathy Overview

3. Pipeline Therapeutics

    --  An Overview of Pipeline Products for Diabetic Nephropathy

4. Comparative Analysis

5. Products in Clinical Stage

    --  Product Description
    --  Research and Development
    --  Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

    --  Product Description
    --  Research and Development
    --  Product Development Activities

7. Therapeutic Assessment

    --  Assessment by Route of Administration
    --  Assessment by Stage and Route of Administration
    --  Assessment by Molecule Type
    --  Assessment by Stage and Molecule Type

8. Inactive Products

    --  Product Description
    --  Research and Development
    --  Product Development Activities

Appendix

Companies Mentioned (Partial List) 

    --  AbbVie Inc
    --  Allergan Plc
    --  Antisense Therapeutics Ltd
    --  Aptevo Therapeutics Inc
    --  Araim Pharmaceuticals Inc
    --  Arena Pharmaceuticals Inc
    --  AstraZeneca Plc
    --  Bayer AG
    --  BLR Bio LLC
    --  Boehringer Ingelheim GmbH
    --  Cellmid Ltd
    --  ChemoCentryx Inc
    --  CSL Ltd
    --  Daiichi Sankyo Company Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/n2b9gg/diabetic?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/diabetic-nephropathy-pipeline-insight-report-2019-pipeline-under-development-therapeutics-scenario-and-growth-prospects-300818508.html

SOURCE Research and Markets